[Treatment of auto-immune diseases with special reference to their pulmonary manifestations (author's transl)].
The treatment of the Goodpasture syndrome, collagenoses (rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis/scleroderma, matosus, progressive systemic sclerosis/scleroderma, dermatomyositis/polymyositis), necrotizing angiitis (periarteritis nodosa, Wegener's granulomatosis) and idiopathic pulmonary fibrosis is reviewed. Their pathogenesis and morbid anatomy is outlined. The uncommunness of these disorders and their pulmonary manifestations is emphasized. The most frequently employed therapeutic agent are the corticosteroids together with acetylsalicylic acid and indomethacin. The effectiveness of immuno-suppressive and cytostatic drugs (azothioprine, cyclophosphamide, chlorambucil) and of D-penicillamine in the treatment of the different disorders is described. Standard programmes for treating any of these diseases have not yet emerged; the long-term results tend do be unsatisfactory. Co-operation with other specialists (nephrologists, rheumatologists, dermatologists) is often necessary in the treatment of these disorders.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D019867:Anti-Glomerular Basement Membrane Disease / Q000188:drug therapy*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000628:therapy*; D003095:Collagen Diseases / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D008511:Medicine; D010348:Patient Care Team; D011658:Pulmonary Fibrosis / Q000188:drug therapy; D013038:Specialization
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D001241:Aspirin; D007213:Indomethacin
Aspekte der Therapie von Autoimmunerkrankungen, unter besonderer Berücksichtigung ihrer pulmonalen Manifestationen.